Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review.
Kristin Harris, Kellie E Murphy, Daphne Horn...
https://pubmed.ncbi.nlm.nih.gov/31285168/Actively Recruiting
Led by Jefferson Drapkin · Updated on 2026-09-17
348
Participants Needed
1
Research Sites
8 weeks
Total Duration
This research aims to evaluate whether cabergoline can prevent lactation and reduce breast symptoms in pregnant individuals aged 18 years or older who undergo abortion or pregnancy loss between 12 and 18 weeks of gestation. The study focuses on how cabergoline affects the proportion of participants experiencing breast symptoms such as engorgement, milk leakage, tenderness, and the need for pain relief, compared with placebo. It also seeks to better understand the frequency and severity of these symptoms during the early second trimester. Participants are randomly assigned to receive either a single oral dose of cabergoline 1 mg or a placebo approximately one hour after their abortion or pregnancy loss procedure. Before the procedure, participants complete a baseline survey assessing breast symptoms. Follow-up surveys measuring symptom presence, severity, and bother occur on days 2, 3, 4, 7, and 14 after the procedure. A subset of about 20 participants may provide optional blood samples at selected times to measure serum prolactin levels, which help assess the biological impact of cabergoline. Throughout the study, participants complete multiple surveys using a validated breast symptoms inventory to evaluate engorgement, milk leakage, tenderness, and pain relief needs. Researchers primarily measure the proportion experiencing breast symptoms four days after the procedure, along with symptom severity, bother, and satisfaction. The study monitors participants for up to 14 days post-procedure, aiming to improve care and comfort for those experiencing abortion or pregnancy loss in the early second trimester.
CONDITIONS
Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms
J
June Ng, MD
O
Olivia Sher, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Jefferson Drapkin
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Cabergoline | Placebo |
|---|---|---|
| what it is | A single 1 mg oral dose of cabergoline given after an abortion or pregnancy loss to inhibit lactation and reduce breast symptoms. | A single oral placebo dose matching cabergoline given after the abortion or pregnancy loss, containing no active medication. |
| role in trial | Investigational intervention to inhibit lactation and alleviate breast symptoms. | Control comparator given to assess the effect of cabergoline versus no active medication. |
| primary use | Prevent lactation and reduce breast symptoms including engorgement, tenderness, milk leakage after abortion or pregnancy loss. | No active effect; serves as control condition to compare against investigational effect. |
| how it is given or performed | Single oral dose of cabergoline approximately one hour after the procedure. | Single oral placebo dose administered approximately one hour after the procedure. |
| evidence status | Significantly fewer participants reported breast symptoms at day 4 compared to placebo (27.8 % vs 97.0 %, P < .001), with persistent differences through day 14. | The majority experienced breast symptoms by day 4 (97.0 %), indicating no inhibition of lactation. |
| important risks | Mostly well tolerated; reported side effects include constipation, fatigue and headache; no major safety concerns noted. | As an inactive comparator, no drug‑related side effects expected beyond placebo effects. |
| important limitations | Only tested as single dose in 12‑18 week abortion population; applicability beyond this group or later timepoints is not established. | No active effect; serving only as control limits insight into how cabergoline compares to existing non‑pharmacologic care. |
| patient impact | Participants had substantially reduced breast symptoms and less bother over the first 14 days post‑procedure. | Most participants experienced significant breast symptoms and bother in the first days after procedure. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 14 days
Participants receive a single oral dose of cabergoline or placebo about one hour after their abortion or pregnancy loss procedure. They complete surveys before the procedure and on days 2, 3, 4, 7, and 14 after the procedure to report breast symptoms and related discomfort.
Follow-up surveys on days 2, 3, 4, 7, and 14
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kristin Harris, Kellie E Murphy, Daphne Horn...
https://pubmed.ncbi.nlm.nih.gov/31285168/Yang Yang, Isabelle Boucoiran, Karen J Tulloch...
https://pubmed.ncbi.nlm.nih.gov/32210637/A Nyboe Andersen, P Damm, A Tabor...
https://pubmed.ncbi.nlm.nih.gov/2220345/W F Rayburn
https://pubmed.ncbi.nlm.nih.gov/8672187/G Giorda, S de Vincentiis, T Motta...
https://pubmed.ncbi.nlm.nih.gov/2037265/Andrea Henkel, Erica P Cahill, Sonia Chavez...
https://pubmed.ncbi.nlm.nih.gov/41538804/Andrea Henkel, Sarah A Johnson, Matthew F Reeves...
https://pubmed.ncbi.nlm.nih.gov/37486652/N Bernard, H Jantzem, M Becker...
https://pubmed.ncbi.nlm.nih.gov/25761676/Jefferson Drapkin
Lead Sponsor